Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
APOA5 116519 CERIVASTATIN CHEMBL1477 PharmGKB

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
APOA5 rs662799 AG + GG fenofibrate efficacy not stated When combined with rs780094 CT + TT genotypes. This combined genotype group is associated with a greater reduction in triacylglycerol concentrations between baseline and 3 weeks of treatment, as compared to any other genotype combination. Adjusted for baseline triacylglycerol. Please note alleles have been complemented to the plus chromosomal strand. Genotypes AG + GG are associated with increased response to fenofibrate in people with Hypertriglyceridemia. 19056598 982044712
APOA5 rs662799 AG + GG fenofibrate efficacy no No significant difference in the change in plasma triglyceride (TG) or high-density lipoprotein (HDL) levels between genotypes was seen, after three weeks of treatment with fenofibrate. Genotypes AG + GG are not associated with response to fenofibrate in people with Hypertriglyceridemia as compared to genotype AA. 19057464 982037995
APOA5 rs662799 AA atorvastatin other yes The correlation between APoB concentration and LDL cholesterol before and after treatment changed only slightly for the AG+GG genotypes (before rho = 0.55 p <0.001; after rho = 0.50 p<0.001) but decreased significantly for the AA genotype (before rho = 0.78 p<0.001; after rho 0.44 p<0.001) showing that the absolute reduction of ApoB was much smaller than the statin-induced reduction of LDLc. Please note: alleles have been complemented to the + chromosomal strand. Genotype AA is associated with response to atorvastatin, rosuvastatin and simvastatin in people with Dyslipidaemia as compared to genotypes AG + GG. 29695967 1449311045
APOA5 rs662799 AA simvastatin efficacy yes Subjects were randomized to receive one of three dose-adjusted statins (N = 65 rosuvastatin, N= 65 atorvastatin, N= 65 simvastatin) and cholesterol (HDL, LDL), triglycerides and free-fatty acids (FFA) were compared between groups before and after statin treatment. Please note: alleles have been complemented to the + chromosomal strand. Genotype AA is associated with increased response to simvastatin in people with Dyslipidaemia as compared to genotypes AG + GG. 29695967 1449311002
APOA5 rs3135506 CG + GG fenofibrate efficacy yes No significant differences in the change of low density lipoprotein cholesterol (LDL-C), total cholesterol (TC), C-reactive protein (CRP), very low density lipoprotein (VLDL) size (units = nm) or high density lipoprotein (HDL) size based on genotype was seen, between baseline and 3 weeks of fenofibrate treatment. Genotypes CG + GG are not associated with response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC. 17431185 982037327
APOA5 rs3135506 CG + GG fenofibrate efficacy not stated When combined with rs780094 CT + TT genotypes. This combined genotype group is associated with a greater reduction in triacylglycerol concentrations between baseline and 3 weeks of treatment, as compared to any other genotype combination. Adjusted for baseline triacylglycerol. Genotypes CG + GG are associated with increased response to fenofibrate in people with Hypertriglyceridemia. 19056598 982044699
APOA5 rs3135506 CG + GG fenofibrate efficacy yes Carriers of the G allele had a significantly greater decrease in triglyceride (TG) levels and a significantly greater increases in high density lipoprotein cholesterol (HDL-C) levels and in low density lipoprotein size (units = nm) between baseline and 3 weeks of fenofibrate treatment, compared to CC homozygotes. Genotypes CG + GG are associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC. 17431185 982037259
APOA5 rs3135506 CC + CG fenofibrate efficacy yes Carriers of the C allele had greater decreases in plasma triglyceride (TG) and high-density lipoprotein (HDL) levels over 3 weeks of treatment, as compared to GG homozygotes. Genotypes CC + CG are associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype GG. 19057464 982037980
APOA5 rs662799 AG + GG fenofibrate efficacy no No difference in the change of triglycerides (TG) levels, high density lipoprotein cholesterol (HDL-C) levels, low density lipoprotein (LDL) levels, total cholesterol (TC) levels, C-reactive protein (CRP) levels, very low density lipoprotein (VLDL) size, HDL size or LDL size was seen based on genotype, and between baseline and 3 weeks of treatment. Please note alleles have been complemented to the plus chromosomal strand. Genotypes AG + GG are not associated with response to fenofibrate in people with Hypertriglyceridemia as compared to genotype AA. 17431185 982037275
APOA5 rs662799 AA rosuvastatin efficacy yes Subjects were randomized to receive one of three dose-adjusted statins (N = 65 rosuvastatin, N= 65 atorvastatin, N= 65 simvastatin) and cholesterol (HDL, LDL), triglycerides and free-fatty acids (FFA) were compared between groups before and after statin treatment. Please note: alleles have been complemented to the + chromosomal strand. Genotype AA is associated with increased response to rosuvastatin in people with Dyslipidaemia as compared to genotypes AG + GG. 29695967 1449311028
APOA5 rs662799 AA atorvastatin efficacy yes Subjects were randomized to receive one of three dose-adjusted statins (N = 65 rosuvastatin, N= 65 atorvastatin, N= 65 simvastatin) and cholesterol (HDL, LDL), triglycerides and free-fatty acids (FFA) were compared between groups before and after statin treatment. Please note: alleles have been complemented to the + chromosomal strand. Genotype AA is associated with increased response to atorvastatin in people with Dyslipidaemia as compared to genotypes AG + GG. 29695967 1449311019